Bloomberg Businessweek ICYMI: Elanco Shares Jump After 2Q Beat-and-Raise Results
Aug 8, 2025
Jeff Simmons, the President and CEO of Elanco Animal Health, shares insights on the company's recent stock surge following impressive second-quarter results. He discusses the launch of innovative dog medications, including Credelio Quattro and Zenrelia, designed to address canine health challenges. Simmons also dives into Elanco's strategic framework aimed at sustainable value creation and the significance of American manufacturing in the animal health sector. The conversation highlights the balance between personal connections with pets and business growth opportunities.
AI Snips
Chapters
Transcript
Episode notes
Animal Health Shows Durable Resilience
- The animal health industry shows exceptional resilience driven by rising pet ownership and protein demand.
- Jeff Simmons says the sector has grown every year in the last three decades except 2008, underlining durable tailwinds.
Focused Pipeline Fuels Growth
- Elanco is prioritizing a focused innovation pipeline to drive growth and customer value.
- Jeff Simmons highlights five major products with blockbuster potential, each targeting large markets.
Credelio Quattro Gains Rapid Share
- Credelio Quattro pairs four active ingredients to broaden flea, tick and heartworm protection in dogs.
- Jeff Simmons says Elanco captured about 14% share in months within a $6 billion parasiticide market growing ~40%.